title: A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
abstract: BACKGROUND
  A 71-year-old woman was referred to a surgical oncology clinic after CT raised suspicion for a bladder neoplasm. She had previously undergone right hemicolectomy and received adjuvant chemotherapy for pT3N1MX cancer of the cecum. A retroperitoneal recurrence had been deemed unsuitable for surgical resection, and had instead been treated with chemoradiation therapy. Follow-up CT raised suspicion for a possible bladder neoplasm.
  
  
  METHODS
  CT, physical examination, urinalysis, cystoscopy with biopsy, pathological analysis and immunohistochemical analysis.
  
  
  METHODS
  Adenocarcinoma of the cecum metastatic to the bladder.
  
  
  RESULTS
  The patient underwent open bladder resection with total excision of the neoplasm and was administered adjuvant chemotherapy consisting of irinotecan and cetuximab. Subsequent recurrences at the same site were treated with transurethral resection, while chemotherapy was still in progress. At 7 months' follow-up, the patient remained alive, with no evidence of further recurrence.
authors.affiliation: La Sapienza University, Rome, Italy. luciano.izzo@uniroma1.it
authors.forename: Luciano
authors.initials: L
authors.lastname: Izzo
authors.forename: Dario
authors.initials: D
authors.lastname: Pietrasanta
authors.forename: Paolo
authors.initials: P
authors.lastname: Izzo
authors.forename: Maria
authors.initials: M
authors.lastname: Caputo
authors.forename: Pierfrancesco
authors.initials: P
authors.lastname: Di Cello
authors.forename: Paolo
authors.initials: P
authors.lastname: Meloni
authors.forename: Antonio
authors.initials: A
authors.lastname: Bolognese
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002430:Cecal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D003082:Colectomy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D000077146:Irinotecan; D002955:Leucovorin / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000556:secondary; D012447:Sacrum / Q000473:pathology; D013876:Thiophenes / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary* / Q000601:surgery
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D000077146:Irinotecan; C068874:raltitrexed; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin